ATP13A2 and colorectal carcinoma: Ultimately, only the ATP13A2 showed consistent trends across the two databases (Figure 1C–E).In addition, we detected higher ATP13A2 expression in the CMS3 type among molecular subtypes of CRC in TCGA (Figure 1F), and the CMS3 type of CRC is mainly characterized by the dysregulation of various metabolic pathways.36